Anuh Pharma (506260) Q4 04/05 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 04/05 earnings summary
23 Oct, 2026Executive summary
FY05 sales and operating income declined 3.4% to Rs. 517.0 million; stiff competition reduced margins and profit before tax.
Profit after tax was Rs. 46.6 million, down from Rs. 60.3 million; directors recommended a dividend of Rs. 20 per equity share.
Financial highlights
Net sales and operating income were Rs. 517.0 million versus Rs. 535.5 million in FY04; gross sales were Rs. 539.6 million versus Rs. 555.4 million.
Profit before tax fell to Rs. 71.8 million from Rs. 83.0 million; profit after tax fell to Rs. 46.6 million from Rs. 60.3 million.
Other income rose to Rs. 22.2 million from Rs. 19.2 million, including Rs. 17.1 million profit on sale of investments.
Outlook and guidance
Planned export sales of Rs. 400 million, alongside greater focus on domestic sales following the loss of export incentives.
New factory unit expected to add ~70% production capacity and be commissioned in January 2006.
Latest events from Anuh Pharma
- Sales and exports grew as the new Tarapur API facility came on stream.506260
Q4 06/07 - Profit rose despite weaker sales; a 1:1 bonus issue and 50% dividend were proposed.506260Q4 97/98
- Profit rose despite falling sales, with export growth and deposit-compliance concerns.506260Q4 98/99
- Sales rose 50% and exports climbed to Rs 99.03m as PAT reached Rs 24.34m.506260Q4 99/00
- PAT rose to ₹39.80m as exports grew and Tarapur capacity expansion began.506260Q4 01/02
- Sales grew 11.6%, exports surged, and PAT softened; dividend rose to ₹12.50/share.506260Q4 02/03
- Sales rose 50.1%, exports 46.5%, and PAT reached Rs 60.3m in FY04.506260Q4 03/04
- Sales rose 49.14%, PAT grew 41.57%, and the new factory came on stream.506260Q4 05/06
- FY08 sales rose 35%, PAT grew 13.29%, and 150 MT of capacity was planned.506260Q4 07/08